Wegovy was originally developed to treat type 2 diabetes. The active ingredient, semaglutide, was created by Novo Nordisk as a more stable version of a natural gut hormone called GLP-1, which helps regulate blood sugar after meals. It first reached patients under the brand name Ozempic, approved by the FDA in 2017 for managing type 2 diabetes. Wegovy came later as a higher-dose version of the same drug, repackaged and approved specifically for chronic weight management.
From Diabetes Drug to Weight Loss Treatment
The story starts with a class of hormones called incretins. After you eat, your gut releases GLP-1, which signals your pancreas to produce insulin and helps keep blood sugar levels steady. Researchers at Novo Nordisk recognized that a synthetic, longer-lasting version of this hormone could offer a new way to treat diabetes. The natural hormone breaks down in minutes, so the challenge was engineering a version that would last long enough to be useful as a once-weekly injection.
The result was semaglutide. When tested in people with type 2 diabetes, it lowered blood sugar effectively, but something else caught researchers’ attention: patients were also losing significant weight. GLP-1 doesn’t just act on the pancreas. It also slows stomach emptying and affects appetite signals in the brain, which means people feel full sooner and stay satisfied longer. That side effect turned out to be medically significant enough to pursue as its own treatment.
How Ozempic and Wegovy Differ
Ozempic and Wegovy contain the exact same molecule, semaglutide, but they’re prescribed at different doses for different purposes. Ozempic maxes out at 2 mg per week and is indicated for type 2 diabetes. Wegovy goes up to 2.4 mg per week and is approved for chronic weight management in adults with obesity or those who are overweight with at least one weight-related health condition.
Both are injected once a week under the skin, typically in the stomach, thigh, or upper arm. The dose ramps up gradually over several months to reduce side effects like nausea, which is the most common complaint during the early weeks. Despite being the same drug, Ozempic and Wegovy are not interchangeable prescriptions. Your dose, your diagnosis, and your insurance coverage all depend on which brand is prescribed.
The Cardiovascular Surprise
Weight loss drugs have a troubled regulatory history, with several pulled from the market over heart safety concerns. So when the FDA required a large cardiovascular safety trial for Wegovy, the expectation was simply to confirm it didn’t cause harm. Instead, the results showed a clear benefit.
In a trial of more than 17,600 participants, major cardiovascular events (heart attack, stroke, or death from cardiovascular causes) occurred in 6.5% of people taking Wegovy compared to 8% of those on a placebo. That 20% relative reduction was striking enough that in March 2024, the FDA approved Wegovy as the first drug specifically indicated to reduce the risk of serious heart problems in adults with obesity or overweight who already have established cardiovascular disease. This approval marked a shift in how obesity medications are viewed: not just as tools for weight loss, but as treatments that can directly protect the heart.
Why the Original Purpose Still Matters
Understanding that Wegovy started as a diabetes treatment helps explain several things patients often wonder about. It clarifies why the drug can lower blood sugar in people who don’t have diabetes, sometimes enough to cause lightheadedness or shakiness if meals are skipped. It explains why doctors monitor blood sugar levels during treatment, even in patients without a diabetes diagnosis. And it puts the weight loss effect in context: semaglutide wasn’t engineered from scratch as a diet drug. The appetite suppression comes from mimicking a hormone your body already produces, which is why the mechanism feels more like reduced hunger than stimulant-driven energy or jitteriness.
The diabetes roots also explain why stopping the medication often leads to weight regain. The drug replaces a hormonal signal rather than permanently changing your metabolism. When that signal disappears, appetite and blood sugar regulation return to their previous patterns. This is consistent with how the drug works in diabetes as well: blood sugar control typically worsens when patients stop taking Ozempic.